The emerging role of microRNAs and long noncoding RNAs in drug resistance of hepatocellular carcinoma

Molecular Cancer, Journal Year: 2019, Volume and Issue: 18(1)

Published: Oct. 25, 2019

Abstract Hepatocellular carcinoma (HCC) is the fifth most common malignancy worldwide and second lethal human cancer. A portion of patients with advanced HCC can significantly benefit from treatments sorafenib, adriamycin, 5-fluorouracil platinum drugs. However, eventually develop drug resistance, resulting in a poor prognosis. The mechanisms involved resistance are complex inconclusive. Human transcripts without protein-coding potential known as noncoding RNAs (ncRNAs), including microRNAs (miRNAs), small nucleolar (snoRNAs), long (lncRNAs) circular RNA (circRNA). Accumulated evidences demonstrate that several deregulated miRNAs lncRNAs important regulators development which elucidates their clinical implications. In this review, we summarized detailed by affect resistance. Multiple tumor-specific may serve novel therapeutic targets prognostic biomarkers for HCC.

Language: Английский

---

Role of non-coding RNAs and RNA modifiers in cancer therapy resistance

Molecular Cancer, Journal Year: 2020, Volume and Issue: 19(1)

Published: March 2, 2020

Abstract As the standard treatments for cancer, chemotherapy and radiotherapy have been widely applied to clinical practice worldwide. However, resistance cancer therapies is a major challenge in clinics scientific research, resulting tumor recurrence metastasis. The mechanisms of therapy are complicated result from multiple factors. Among them, non-coding RNAs (ncRNAs), along with their modifiers, investigated play key roles regulating development mediating within various cancers, such as hepatocellular carcinoma, breast lung gastric etc. In this review, we attempt elucidate underlying ncRNA/modifier-modulated radiotherapy, providing some therapeutic potential points future treatment.

Language: Английский

---

Long noncoding RNA (lncRNA) EIF3J-DT induces chemoresistance of gastric cancer via autophagy activation

Autophagy, Journal Year: 2021, Volume and Issue: 17(12), P. 4083 - 4101

Published: March 25, 2021

Chemotherapy is currently the main treatment for unresectable or advanced postoperative gastric cancers. However, its efficacy negatively affected by occurrence of chemoresistance, which severely affects patient prognosis. Recently, dysregulation in autophagy has been suggested as a potential mechanism chemoresistence, and long noncoding RNA (lncRNA) also shows regulatory role cancer drug resistance. Using sequencing, we found that lncRNA EIF3J-DT was highly expressed drug-resistant cells. In-vitro in-vivo experiments showed activated induced resistance cells targeting ATG14. Bioinformatics experimental results regulated expression ATG14 through direct binding to enhance stabilization mRNA via blocking degradation competitively with microRNA (miRNA) MIR188-3p. Therefore, increased ATG14, contributing activation chemoresistance. Furthermore, it confirmed were patients resistant chemotherapy, this closely associated In conclusion, involved regulation chemoresistance It may be suitable new target enhancing chemosensitivity improving prognosis.Abbreviations: 3-MA: 3-methyladenine; 5-Fu: 5-fluorouracil; ATG: related; C-CASP3: cleaved caspase 3; C-CASP7: 7; C-PARP: PARP; CQ: chloroquine; CR: complete response; DIG: digoxigenin; ESR1: estrogen receptor 1; FBS: fetal bovine serum; FISH: fluorescence situ hybridization; IHC: immunohistochemistry; ISH: lncRNA: RNA; miRNA: microRNA; MUT: mutant; NC: negative control; OXA: oxaliplatin; PBS: phosphate-buffered saline; PD: progressive disease; PFA: paraformaldehyde; PR: partial qPCR: quantitative polymerase chain reaction; RAPA: rapamycin; SD: stable TEM: transmission electron microscopy; WT: wild type.

Language: Английский

---

The role of non-coding RNAs in ABC transporters regulation and their clinical implications of multidrug resistance in cancer

Expert Opinion on Drug Metabolism & Toxicology, Journal Year: 2021, Volume and Issue: 17(3), P. 291 - 306

Published: Feb. 7, 2021

Multi-drug resistance (MDR) is a hindrance toward the successful treatment of cancers. The primary mechanism that gives rise to acquired chemoresistance overexpression adenosine triphosphate-binding cassette (ABC) transporters. dysregulation non-coding RNAs (ncRNAs) widely concerned reason contributing this phenotype.In review, we describe role intracellular and exosomal ncRNAs including microRNAs (miRNAs), long (lncRNAs), circular (circRNAs) in ABC transporters-induced tumor MDR. Meanwhile, will introduce potential therapeutic strategies which reverse MDR terms reducing expression transporters via targeting ncRNAs, like nucleic acid delivery with nanoparticles as well miRNAs-targeted small molecular compounds.The dysregulated ncRNAs-mediated chemo-resistant cancer not negligible. Finding out underlying may provide theoretical basis for clinical therapy MDR, emergence new approaches gene suppress makes reversing possible despite its application requires further investigations. Also, discovered regulating cancers are just tip iceberg genetic transcripts, especially circRNAs, justify more concern.Abbreviations: multi-drug resistance; ABC, cassette; NcRNAs, RNAs; MiRNAs, microRNAs; LncRNAs, CircRNAs, CeRNAs, competing endogenous 3'UTR, 3'-untranslated regions; SLC, solute carrier; ABCB1/MDR1, subfamily B member 1; ABCG2/BCRP, G 2; ABCCs/MRPs, C 1 12; DLL1: Delta-like protein DTX, docetaxel; DOX/ADM/ADR, doxorubicin/adriamycin; PTX, paclitaxel; VBL, vinblastine; VCR, vincristine; MTX, methotrexate; CDDP/DDP, cisplatin/cis-diaminedichloroplatinum; OXA/L-OHP, oxaliplatin; TMZ, temozolomide; 5-FU, 5-fluorouracil; MTA, pemetrexed; NSCLC, non-small cell lung carcinoma; HCC, hepatocellular CRC, colorectal RB, retinoblastoma; RCC, renal OS, osteosarcoma; PDAC, pancreatic ductal adenocarcinoma; TNBC, triple-negative breast cancer.

Language: Английский

---

Utilizing non-coding RNA-mediated regulation of ATP binding cassette (ABC) transporters to overcome multidrug resistance to cancer chemotherapy

Drug Resistance Updates, Journal Year: 2024, Volume and Issue: 73, P. 101058 - 101058

Published: Jan. 19, 2024

Language: Английский

---

Long non-coding RNAs as a determinant of cancer drug resistance: Towards the overcoming of chemoresistance via modulation of lncRNAs

Drug Resistance Updates, Journal Year: 2020, Volume and Issue: 50, P. 100683 - 100683

Published: Feb. 25, 2020

Language: Английский

---

Non-coding RNA in drug resistance of hepatocellular carcinoma

Bioscience Reports, Journal Year: 2018, Volume and Issue: 38(5)

Published: Sept. 17, 2018

Hepatocellular carcinoma (HCC) has been one of the most highly lethal cancers. The acquisition drug resistance accounts for majority poor effects chemotherapy in HCC. Non-coding RNAs (ncRNAs) including miRNAs, long ncRNAs (lncRNAs), and circular RNA (circRNA) have well-documented to participate cancer occurrence progression. Recently, multiple studies highlighted key roles chemoresistance In addition, accumulating evidence demonstrated that they can serve as biomarkers diagnosis, treatment, prognosis this review, we first overviewed up-to-date findings regarding miRNA lncRNA HCC, then summarized specific mechanisms modulate finally discussed their potential clinical application overcoming obstacle HCC future.

Language: Английский

---

LncRNA CACS15 contributes to oxaliplatin resistance in colorectal cancer by positively regulating ABCC1 through sponging miR-145

Archives of Biochemistry and Biophysics, Journal Year: 2019, Volume and Issue: 663, P. 183 - 191

Published: Jan. 9, 2019

Language: Английский

---

Long non‐coding RNA SNHG20 promotes the tumorigenesis of oral squamous cell carcinoma via targeting miR‐197/LIN28 axis

Journal of Cellular and Molecular Medicine, Journal Year: 2018, Volume and Issue: 23(1), P. 680 - 688

Published: Nov. 5, 2018

Abstract Long non‐coding RNA (lnc ) has been verified to participate in the tumour regulation, including oral squamous cell carcinoma ( OSCC ). Nevertheless, role of lnc SNHG 20 on still remains elusive. Here, we investigate physiopathologic functions tumorigenesis and explore its potential mechanism. Lnc was up‐regulated tissue compared with adjacent non‐tumour tissue. Meanwhile, overexpressed cancer stem‐like cells. In vitro vivo, loss‐of‐function experiments showed that knockdown inhibited proliferative ability, mammosphere‐forming ALDH 1 expression, stem factors LIN 28, Nanog, Oct4, SOX 2) growth. Bioinformatics luciferase reporter assay revealed miR‐197 targeted 3′‐untranslated regions 28 by complementary binding. Validation confirmed associated 20/miR‐197/ axis proliferation stemness. summary, our results reveal important function oncogenesis stemness , suggesting vital tumorigenesis.

Language: Английский

---

lncRNA NR2F1‐AS1 promotes breast cancer angiogenesis through activating IGF‐1/IGF‐1R/ERK pathway

Journal of Cellular and Molecular Medicine, Journal Year: 2020, Volume and Issue: 24(14), P. 8236 - 8247

Published: June 17, 2020

Abstract Long non‐coding RNAs (lncRNAs) take various effects in cancer mostly through sponging with microRNAs (miRNAs). lncRNA NR2F1‐AS1 is found to promote tumour progression hepatocellular carcinoma, endometrial and thyroid cancer. However, the role of breast angiogenesis remains unknown. In this study, we was positively related CD31 CD34 Pearson's correlation analysis, while transfection promoted human umbilical vascular endothelial cell (HUVEC) tube formation. cells, enhanced HUVEC proliferation, formation migration ability tumour‐conditioned medium (TCM). zebrafish model, increased cell‐related neo‐vasculature subsequently metastasis. mouse vessel formation, micro density (MVD) then induced growth primary tumour. Mechanically, insulin‐like factor‐1 (IGF‐1) expression miRNA‐338‐3p cells activated receptor IGF‐1 (IGF‐1R) extracellular signal‐regulated kinase (ERK) pathway HUVECs. These results indicated that could IGF‐1/IGF‐1R/ERK pathway.

Language: Английский

---